PJEQX
Price
$16.29
Change
-$0.06 (-0.37%)
Updated
Sep 20 closing price
VGSNX
Price
$21.46
Change
-$0.07 (-0.33%)
Updated
Sep 20 closing price
Ad is loading...

PJEQX vs VGSNX

Header iconPJEQX vs VGSNX Comparison
Open Charts PJEQX vs VGSNXBanner chart's image
PGIM US Real Estate R6
Price$16.29
Change-$0.06 (-0.37%)
VolumeN/A
CapitalizationN/A
Vanguard Real Estate Index Institutional
Price$21.46
Change-$0.07 (-0.33%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
PJEQX vs VGSNX Comparison Chart
Loading...
VS
PJEQX vs. VGSNX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PJEQX is a Buy and VGSNX is a Buy.

FUNDAMENTALS
Fundamentals
VGSNX has more cash in the bank: 70.5B vs. PJEQX (113M). VGSNX pays higher dividends than PJEQX: VGSNX (4.01) vs PJEQX (1.82). PJEQX was incepted earlier than VGSNX: PJEQX (7 years) vs VGSNX (21 years). PJEQX is a more actively managed with annual turnover of: 156.00 vs. VGSNX (9.00). PJEQX has a lower initial minimum investment than VGSNX: PJEQX (0) vs VGSNX (5000000). PJEQX (28.26) and VGSNX (26.90) have marching annual gain over last year. VGSNX return over 5 years is better than : 26.84 vs. PJEQX (24.80).
PJEQXVGSNXPJEQX / VGSNX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence7 years21 years-
Gain YTD18.89713.452140%
Front LoadN/AN/A-
Min. Initial Investment05000000-
Min. Initial Investment IRAN/AN/A-
Net Assets113M70.5B0%
Annual Yield % from dividends1.824.0145%
Returns for 1 year28.2626.90105%
Returns for 3 years2.373.6465%
Returns for 5 years24.8026.8492%
Returns for 10 yearsN/A87.29-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KPRX3.620.16
+4.62%
Kiora Pharmaceuticals Inc.
TRU101.141.17
+1.17%
TransUnion
SVRA4.440.01
+0.23%
Savara
KYMR46.44-0.86
-1.82%
Kymera Therapeutics
GALT2.71-0.06
-2.17%
Galectin Therapeutics